Install
- 373articles · 365d
- 2+ day agolatest article
- Jan 1, 2026earliest in window
- 54%with images
- 257avg words
- Medical 338
- Health & Wellness 329
- Health 274
- Education 40
- Science & Technology 19
- Disaster, Accident & Emergency Incident 15
- Human Interest 13
- Jobs & Education 13
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma
3+ day, 15+ hour ago (358+ words) Allen Khudaverdyan, MD, NYU Grossman School of Medicine, New York, New York, discusses results from a large retrospective analysis evaluating the association between concurrent statin use and overall survival in patients with head and neck squamous cell carcinoma treated with…...
Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma
4+ day, 16+ hour ago (652+ words) Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses how findings from the phase 3 HERIZON-GEA-01 trial are reshaping first-line treatment of HER2-positive gastroesophageal adenocarcinoma following the approval of zanidatamab plus chemotherapy, with or without tislelizumab. He…...
FDA Approves Camizestrant Plus CDK4/6 Inhibitor Following Emergence of ESR1 Mutation in Advanced Breast Cancer
4+ day, 19+ hour ago (273+ words) Based on results from the phase 3 SERENA-6 trial, the US Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah; AstraZeneca) in combination with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following detection…...
Molecularly Guided Treatment Intensification in Metastatic Prostate Cancer
2+ week, 2+ day ago (839+ words) Andrew Hahn, MD, MD Anderson Cancer Center, Houston, Texas, presents a case of de novo metastatic prostate cancer to illustrate how comprehensive molecular profiling can inform upfront treatment selection. Hi, my name is Andy Hahn, I'm an assistant professor of…...
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
2+ week, 4+ day ago (192+ words) The approval of zanidatamab plus tislelizumab and chemotherapy applies to patients with HER2 IHC 3+ or IHC 2+/ISH+ tumors, while zanidatamab plus chemotherapy without tislelizumab is approved for patients with HER2 IHC 3+ disease. HER2 positivity must be confirmed using an FDA-approved test. PFS was…...
Defining Optimal Medical Therapy for CLTI in 2026
1+ mon, 5+ day ago (552+ words) HMP Global Learning Network Defining Optimal Medical Therapy for CLTI in 2026 On Friday morning at the Amputation Prevention Symposium, Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, presented a review of the evidence supporting contemporary medical management for patients…...
Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer
1+ mon, 6+ day ago (556+ words) Barbara Burtness, MD, Yale Cancer Center, New Haven, Connecticut, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab monotherapy in patients with recurrent or metastatic HPV-unrelated head and neck squamous cell carcinoma following progression on platinum-based chemotherapy…...
Client Challenge
1+ mon, 1+ week ago (14+ words) AI in Oncology Practice: What APPs Need to Know Now HMP Global Learning Network...
Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer
1+ mon, 2+ week ago (306+ words) Harold Nathan Tan, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses findings from a retrospective analysis evaluating early-phase immunotherapy trials in patients with recurrent or metastatic head and neck squamous cell carcinoma. Good afternoon, everyone, I’m…...
Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer
1+ mon, 2+ week ago (719+ words) HMP Global Learning Network Insights from the ESMO Gastrointestinal Cancers Congress Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer - Design/Population: This phase 1 study evaluated the combination of the KRAS G12D-selective RAS(ON) inhibitor zoldonrasib and…...